The trading group's Marunouchi Capital unit reached its first close while BMS and Alexandria took part in cancer drug developer Torl’s $150m series B round.

Funds Marunouchi Capital, an investment subsidiary of trading firm Mitsubishi Corporation, reached a ¥40.2bn ($303m) first close for its third fund. The unit intends to source external investment to increase its size to ¥100bn. BAI Capital, a China-based venture capital firm that evolved from media conglomerate Bertelsmann’s regional subsidiary, Bertelsmann Asia Investments, is set to…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.